Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Cureus ; 13(4): e14340, 2021 Apr 07.
Article in English | MEDLINE | ID: mdl-33972898

ABSTRACT

Portal vein thrombosis is defined as a clot within the trunk or intrahepatic branches of the portal vein. Sequelae involves either partial or complete recanalization. However, in patients with liver disease, it can progress to a cavernoma instead of recanalization. This can result in gastrointestinal bleeding and intestinal infarction. Its rising incidence in severe acute respiratory syndrome coronavirus 2 is an important clinical aspect that needs to be addressed and treated.

3.
Pancreas ; 47(5): 556-560, 2018.
Article in English | MEDLINE | ID: mdl-29683969

ABSTRACT

OBJECTIVE: The aim of this study is to determine the diagnostic accuracy of preoperative evaluation to detect main pancreatic duct involvement in pancreatic cystic lesions thus differentiating mixed intraductal papillary mucinous neoplasm (IPMN) from branch duct (BD)-IPMN. METHODS: The pathology database of pancreatic resections from 2000 to 2014 was reviewed. Main pancreatic duct-IPMNs and IPMNs with intracystic mass/nodules were excluded. The preoperative test characteristics were analyzed using surgical histopathology as the "gold standard." RESULTS: Sixty BD-IPMNs and 23 mixed-IPMNs were identified. Mixed-IPMNs were larger (mean [standard deviation], 4.14 [2.9] vs 2.74 [1.9] mm; P = 0.03) and demonstrated frequent high-grade dysplasia/adenocarcinoma (43% vs 12%, P = 0.004) than BD-IPMNs. Endoscopic ultrasound (EUS) (sensitivity, 80%; specificity, 78%; accuracy, 79%) had the best diagnostic accuracy, whereas magnetic resonance imaging (MRI) (sensitivity, 83%; specificity, 63%; accuracy, 68%) had the highest sensitivity for the diagnosis of mixed-IPMN. A combination of EUS and MRI reached maximum sensitivity but with decreased accuracy (sensitivity, 100%; specificity, 64%; accuracy, 67%). The area under the curve for receiver operation curve was 0.71 whereas the optimal cyst size to detect main duct involvement was 3 cm. CONCLUSIONS: For preoperative evaluation of pancreatic cystic lesions without evidence of intracystic nodules, a combination of MRI and EUS should be considered for improved detection of main duct involvement.


Subject(s)
Adenocarcinoma, Mucinous/diagnostic imaging , Carcinoma, Pancreatic Ductal/diagnostic imaging , Carcinoma, Papillary/diagnostic imaging , Diagnostic Imaging/methods , Pancreatic Ducts/diagnostic imaging , Pancreatic Neoplasms/diagnostic imaging , Aged , Diagnosis, Differential , Endosonography , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Preoperative Period , Sensitivity and Specificity
4.
Hepatobiliary Pancreat Dis Int ; 16(2): 202-208, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28381386

ABSTRACT

BACKGROUND: High-grade pancreatic intraepithelial neoplasia (PanIN-3), a precursor of pancreatic ductal adenocarcinoma (PDAC), is not universally detected in resected pancreatic neoplasms. We sought to determine the prevalence and prognostic relevance of PanIN-3 lesions in primary surgical resections of PDACs and intraductal papillary mucinous neoplasms (IPMNs). METHODS: A retrospective review of a tertiary care center pathology database (1/2000-6/2014) was performed. Demographics, imaging, pathology, disease-recurrence, and survival data were reviewed. RESULTS: A total of 458 patients who underwent primary pancreatic resection were included. "PanIN-3" lesions were found in 74 (16.2%) patients who either had PDAC (n=67) or main duct (MD)-IPMN (n=7). Among IPMN-MDs, PanIN-3 lesions were exclusively found in those with pathological evidence of chronic pancreatitis. For PDACs, the median overall survival (OS) for pancreata with PanIN-3 lesions was significantly better than those without (OS 1.12 years, inter-quartile range [IQR] 0.72, 2.05 years vs OS 0.86 years, IQR 0.64, 1.60 years respectively; P=0.04). Multivariate Cox regression analysis demonstrated that the presence of PanIN-3 lesions was associated with a reduced risk of death (HR=0.43; 95% CI: 0.23-0.82; P=0.01). CONCLUSIONS: Following primary resection of pancreatic adenocarcinoma, the lower survival observed in patients without PanIN-3 lesions might suggest a state of complete or accelerated transformation. Further investigations are necessary to validate these findings that might impact disease prognosis and management.


Subject(s)
Adenocarcinoma, Papillary/pathology , Carcinoma in Situ/pathology , Carcinoma, Pancreatic Ductal/pathology , Neoplasms, Cystic, Mucinous, and Serous/pathology , Pancreatic Neoplasms/pathology , Adenocarcinoma, Papillary/mortality , Adenocarcinoma, Papillary/surgery , Aged , Carcinoma in Situ/mortality , Carcinoma in Situ/surgery , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/surgery , Chi-Square Distribution , Databases, Factual , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Neoplasm Grading , Neoplasm Recurrence, Local , Neoplasms, Cystic, Mucinous, and Serous/mortality , Neoplasms, Cystic, Mucinous, and Serous/surgery , Ohio , Pancreatectomy , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/surgery , Proportional Hazards Models , Retrospective Studies , Risk Factors , Tertiary Care Centers , Time Factors , Treatment Outcome
8.
Am J Gastroenterol ; 110(11): 1608-19, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26482857

ABSTRACT

OBJECTIVES: Morbid obesity may adversely affect the clinical course of acute pancreatitis (AP); however, there are no inpatient, population-based studies assessing the impact of morbid obesity on AP-related outcomes. We sought to evaluate the impact of morbid obesity on AP-related clinical outcomes and health-care utilization. METHODS: The Nationwide Inpatient Sample (2007-2011) was reviewed to identify all adult inpatients (≥18 years) with a principal diagnosis of AP. The primary clinical outcomes (mortality, renal failure, and respiratory failure) and secondary resource outcomes (length of stay and hospital charges) were analyzed using univariate and multivariate comparisons. Propensity score-matched analysis was performed to compare the outcomes in patients with and without morbid obesity. RESULTS: Morbid obesity was associated with 3.9% (52,297/1,330,302) of all AP admissions. Whereas the mortality rate decreased overall (0.97%→0.83%, P<0.001), it remained unchanged in those with morbid obesity (1.02%→1.07%, P=1.0). Multivariate analysis revealed that morbid obesity was associated with increased mortality (odds ratio (OR) 1.6; 95% confidence interval (CI) 1.3, 1.9), prolonged hospitalization (0.4 days; P<0.001), and higher hospitalization charges ($5,067; P<0.001). A propensity score-matched cohort analysis demonstrated that the primary outcomes, acute kidney failure (10.8 vs. 8.2%; P<0.001), respiratory failure (7.9 vs. 6.4%; P<0.001), and mortality (OR 1.6, 95% CI 1.2, 2.1) were more frequent in morbid obesity. CONCLUSIONS: Morbid obesity negatively influences inpatient hospitalization and is associated with adverse clinical outcomes, including mortality, organ failure, and health-care resource utilization. These observations and the increasing global prevalence of obesity justify ongoing efforts to understand the role of obesity-induced inflammation in the pathogenesis and management of AP.


Subject(s)
Acute Kidney Injury/epidemiology , Obesity, Morbid/epidemiology , Pancreatitis/mortality , Respiratory Insufficiency/epidemiology , Acute Kidney Injury/etiology , Adult , Aged , Comorbidity , Female , Health Services/statistics & numerical data , Hospital Charges/statistics & numerical data , Hospital Mortality , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Obesity, Morbid/economics , Pancreatitis/complications , Pancreatitis/economics , Prevalence , Propensity Score , Respiratory Insufficiency/etiology , United States/epidemiology
10.
Pancreas ; 44(6): 901-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25899649

ABSTRACT

OBJECTIVES: Our objective was to delineate predictive factors differentiating groove pancreatitis (GP) from other lesions involving the head of the pancreas (HOP). METHODS: A case-control study of patients older than 10 years was performed comparing patients with GP to those with other surgically resected HOP lesions. RESULTS: Thirteen patients with GP (mean ± SD age, 51.9 ± 10.5 years; 11 males [84.6%]), all with a history of smoking (mean, 37.54 ± 17.8 pack-years), were identified. Twelve patients (92.3%) had a history of heavy alcohol drinking (heavy alcohol [EtOH]). The mean lesion size was 2.6 ± 1.1 cm, and the CA 19-9 was elevated (>37 IU/mL) in 5 patients (45.5%). The most common histopathologic condition was duodenal wall cyst with myofibroblastic proliferation and changes of chronic pancreatitis in the HOP.Univariate analysis revealed decreasing age, male sex, weight loss, nausea/vomiting, heavy EtOH, smoking, and a history of chronic pancreatitis were predictive of GP. A multivariate analysis among smokers demonstrated that weight loss (P = 0.006; odds ratio, 11.96; 95% confidence interval, 2.1-70.2), and heavy EtOH (P < 0.001; odds ratio, 82.2; 95% confidence interval, 9.16-738.1) were most predictive of GP. Compared to pancreatic adenocarcinoma (n = 183), weight loss and heavy EtOH remained predictive of GP. CONCLUSION: Groove pancreatitis in the HOP is associated with a history of heavy EtOH and weight loss. In the absence of these symptoms, it is essential to rule out a malignant lesion.


Subject(s)
Pancreatic Neoplasms/diagnosis , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/etiology , Adult , Age Factors , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Biopsy , Chi-Square Distribution , Diagnosis, Differential , Diagnostic Imaging/methods , Endoscopy, Gastrointestinal , Female , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Pancreatectomy , Pancreatitis, Chronic/classification , Pancreatitis, Chronic/surgery , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk Factors , Sex Factors , Smoking/adverse effects , Terminology as Topic , Weight Loss
13.
Magn Reson Imaging ; 32(6): 679-83, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24637083

ABSTRACT

Magnetic resonance elastography (MRE) of the liver is a novel noninvasive clinical diagnostic tool to stage fibrosis based on measured stiffness. The purpose of this study is to design, evaluate and validate a rapid MRE acquisition technique for noninvasively quantitating liver stiffness which reduces by half the scan time, thereby decreasing image registration errors between four MRE phase offsets. In vivo liver MRE was performed on 16 healthy volunteers and 14 patients with biopsy-proven liver fibrosis using the standard clinical gradient recalled echo (GRE) MRE sequence (MREs) and a developed rapid GRE MRE sequence (MREr) to obtain the mean stiffness in an axial slice. The mean stiffness values obtained from the entire group using MREs and MREr were 2.72±0.85 kPa and 2.7±0.85 kPa, respectively, representing an insignificant difference. A linear correlation of R(2)=0.99 was determined between stiffness values obtained using MREs and MREr. Therefore, we can conclude that MREr can replace MREs, which reduces the scan time to half of that of the current standard acquisition (MREs), which will facilitate MRE imaging in patients with inability to hold their breath for long periods.


Subject(s)
Elasticity Imaging Techniques/methods , Liver Cirrhosis/diagnosis , Liver Cirrhosis/physiopathology , Magnetic Resonance Imaging/methods , Adult , Biopsy , Female , Humans , Male , Middle Aged
14.
ACG Case Rep J ; 1(3): 143-4, 2014 Apr.
Article in English | MEDLINE | ID: mdl-26157855

ABSTRACT

Recent exponential increase in inferior vena cava (IVC) filter placements has led to a higher rate of filter complications. A 46-year-old man with a past history of IVC filter placement for bilateral deep vein thrombosis presented with lower abdominal pain. Imaging studies demonstrated IVC filter strut penetrations into multiple structures. Upper endoscopy confirmed an uncomplicated single IVC filter strut penetration into the duodenal wall. The abdominal pain was determined to be unrelated to IVC filter strut penetration, and the patient was managed conservatively. Although IVC filter strut penetrations can cause significant complications, current guidelines remain unclear for management of asymptomatic enteric IVC filter strut penetrations.

15.
World J Gastrointest Oncol ; 5(12): 230-4, 2013 Dec 15.
Article in English | MEDLINE | ID: mdl-24363831

ABSTRACT

Post transplant lymphoproliferative disorder (PTLD) represents a life threatening disorder occurring after transplantation, ranging from a polyclonal mononucleosis like illness to a monomorphic high grade neoplasm with cytologic and histopathologic evidence indicative of transformation to lymphoma. PTLD of diffuse large B-cell lymphoma (DLBCL) subtype, isolated to the esophagus is a rare diagnosis. We describe the first case of an immunocompromised adult patient diagnosed with DLBCL-PTLD limited to his esophagus without an associated mass or locoregional lymphadenopathy on imaging since the institution of the revised Cheson criteria, which includes positron emission tomography-computed tomography as the standard staging modality. Even more unique to our case was the suggestion of underlying cytomegalovirus (CMV) gastritis leading to a hypothesis about a less well understood relationship between CMV and Epstein Barr virus (EBV). In the post transplant setting, immunocompromised state, or EBV positive state, upper gastrointestinal symptoms should prompt investigation with an upper endoscopy (EGD). Additionally, specific to our case, the fact that the patients' presentation was suspicious for CMV gastritis raises the possibility that the CMV infection predated his PTLD increasing his risk of acquiring PTLD. This reemphasizes the importance and diagnostic utility of early screening with EGD in patients after transplantation.

17.
World J Gastrointest Endosc ; 5(1): 19-28, 2013 Jan 16.
Article in English | MEDLINE | ID: mdl-23330050

ABSTRACT

Chronic pancreatitis (CP) is a common gastrointestinal illness, which affects the quality of life with substantial morbidity and mortality. The management includes medical, endoscopic and surgical approaches with the need for interaction between various specialties, calling for a concerted multidisciplinary approach. However, at the time of this publication, guidelines to establish care of these patients are lacking. This review provides the reader with a comprehensive overview of the studies summarizing the various treatment options available, including medical, surgical and endoscopic options. In addition, technological advances such as endoscopic retrograde cholangiopancreatogrophy, endoscopic shock wave lithotripsy and endoscopic ultrasound can now be offered with reasonable success for pancreatic decompression, stricture dilatation with stent placement, stone fragmentation, pseudocyst drainage, and other endoscopic interventions such as celiac plexus block for pain relief. We emphasize the endoscopic options in this review, and attempt to extract the most up to date information from the current literature. The treatment of CP and its complications are discussed extensively. Complications such as biliary strictures. pancreatic pseudocysts, and chronic pain are common issues that arise as long-term complications of CP. These often require endoscopic or surgical management and possibly a combination of approaches, however choosing amongst the various therapeutic and palliative modalities while weighing the risks and benefits, makes the management of CP challenging. Treatment goals should be not just to control symptoms but also to prevent disease progression. Our aim in this paper is to advocate and emphasize an evidence based approach for the management of CP and associated long term complications.

18.
Expert Opin Pharmacother ; 9(11): 1963-7, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18627333

ABSTRACT

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening complication which occurs in 1-3% of patients receiving heparin. Patients with untreated HIT have an up to 50% risk of developing life- and limb-threatening thromboembolic complications. Treatment is based upon clinical suspicion, stopping heparin therapy and initiation of anticoagulation with a rapidly acting alternative non-heparin anticoagulant, such as argatroban-a hepatically excreted direct thrombin inhibitor which is effective in the treatment of HIT. OBJECTIVE: To summarize the pharmacological and clinical data, and discuss the impact of argatroban in the current treatment of HIT. METHODS: A literature search was performed with the aid of Pubmed and Google. Search parameters of 'argatroban', 'heparin-induced thrombocytopenia' and 'treatment' were input into both search engines. CONCLUSION: Argatroban is a safe and effective treatment for HIT. In patients taking other hepatically cleared medications, lower initial doses may have to be used to avoid over-anticoagulation.


Subject(s)
Anticoagulants/therapeutic use , Heparin/adverse effects , Pipecolic Acids/therapeutic use , Thrombocytopenia/chemically induced , Anticoagulants/adverse effects , Anticoagulants/pharmacokinetics , Arginine/analogs & derivatives , Clinical Trials as Topic , Humans , Liver/metabolism , Pipecolic Acids/adverse effects , Pipecolic Acids/pharmacokinetics , Sulfonamides , Thrombocytopenia/complications , Thrombocytopenia/drug therapy , Thromboembolism/etiology , Thromboembolism/prevention & control
19.
Pediatr Blood Cancer ; 47(3): 245-54, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16724312

ABSTRACT

Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.


Subject(s)
Blood Donors , Factor IX/adverse effects , Factor VIII/adverse effects , Hemophilia A/therapy , Safety , Blood-Borne Pathogens , Factor IX/therapeutic use , Factor VIII/therapeutic use , Humans , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...